Your browser doesn't support javascript.
loading
Clinical impact of serum soluble SLAMF7 in multiple myeloma.
Ishibashi, Mariko; Soeda, Saori; Sasaki, Makoto; Handa, Hiroshi; Imai, Yoichi; Tanaka, Norina; Tanosaki, Sakae; Ito, Shigeki; Odajima, Takeshi; Sugimori, Hiroki; Asayama, Toshio; Sunakawa, Mika; Kaito, Yuta; Kinoshita, Ryosuke; Kuribayashi, Yasuko; Onodera, Asaka; Moriya, Keiichi; Tanaka, Junji; Tsukune, Yutaka; Komatsu, Norio; Inokuchi, Koiti; Tamura, Hideto.
Afiliación
  • Ishibashi M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Soeda S; Department of Microbiology and Immunology, Nippon Medical School, Tokyo, Japan.
  • Sasaki M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Handa H; Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
  • Imai Y; Department of Hematology, Gunma University, Gunma, Japan.
  • Tanaka N; Department of Hematology and Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Tanosaki S; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
  • Ito S; Department of Hematology, The Fraternity Memorial Hospital, Tokyo, Japan.
  • Odajima T; Department of Clinical Oncology, Iwate Medical University School of Medicine, Iwate, Japan.
  • Sugimori H; Faculty of Health Science, Daito Bunka University Graduate School of Sports and Health Science, Tokyo, Japan.
  • Asayama T; Department of Preventive Medicine, Daito Bunka University Graduate School of Sports and Health Science, Saitama, Japan.
  • Sunakawa M; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Kaito Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Kinoshita R; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Kuribayashi Y; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Onodera A; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Moriya K; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Tanaka J; Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Tsukune Y; Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
  • Komatsu N; Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
  • Inokuchi K; Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
  • Tamura H; Department of Hematology, Nippon Medical School, Tokyo, Japan.
Oncotarget ; 9(78): 34784-34793, 2018 Oct 05.
Article en En | MEDLINE | ID: mdl-30410677
ABSTRACT
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Japón